---
schema_version: "secwatch.filing_event.v1"
accession: "0001827090-23-000008"
form_type: "8-K"
ticker: "CERT"
cik: "0001827090"
company_name: "Certara, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T23:14:32.035557+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Certara Q2 revenue $90.5M, net income $4.7M; lowers FY2023 outlook

## Summary
- Revenue $90.5M (+9% YoY, +10% constant currency); net income $4.7M vs loss $0.6M.
- Adjusted EBITDA $32.4M (+16% YoY); software revenue and bookings each +17% YoY.
- Services revenue +5% YoY but bookings declined; CEO cites cautious spending by small biotech.
- Software renewal rate 93% in Q2; management expects services demand improvement in 2024.
- FY2023 full-year guidance reduced due to lower services growth and slow regulatory recovery.

## SEC filing metadata
- accession: 0001827090-23-000008
- form_type: 8-K
- ticker: CERT
- cik: 0001827090
- company_name: Certara, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827090/000182709023000008/0001827090-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827090/000182709023000008/certara-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001827090-23-000008
- JSON: https://secwatch.observer/filing/0001827090-23-000008.json
- Plain text: https://secwatch.observer/filing/0001827090-23-000008.txt

## Key facts
- Earnings Releases
  Certara, Inc. reported the second quarter of fiscal year 2023 results: revenue $90.5 million, net income $4.7 million. Guidance reaffirmed.
  - Period: the second quarter of fiscal year 2023
  - Revenue: $90.5 million
  - Net income: $4.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. Second Quarter Highlights: • Revenue was $90.5 million, compared to $82.8 million in the second quarter of 2022, representing growth of 9% over the second quarter of 2022 on a reported basis and 10% at constant currency. • Net income
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827090/000182709023000008/0001827090-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.